إسرائيل - العبرية - Ministry of Health

merck sharp & dohme israel ltd - rizatriptan as benzoate - טבליה - rizatriptan as benzoate 5 mg - rizatriptan - rizatriptan - rizalt is indicated for the acute treatment of migraine attacks with or without aura in adults

إسرائيل - العبرية - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - asenapine as maleate - טבליות למתן מתחת ללשון - asenapine as maleate 5 mg - asenapine - asenapine - schizophrenia saphris is indicated for the treatment of schizophrenia in adults. the efficacy of saphris was established in two 6-week trials and one maintenance trial in adults bipolar disorder monotherapy: saphris is indicated for the acute treatment of manic or mixed episodes associated with bipolar i disorder. efficacy was established in two 3-week monotherapy trials in adults adjunctive therapy: saphris is indicated as adjunctive therapy with either lithium or valproate for the acute treatment of manic or mixed episodes associated with bipolar i disorder. efficacy was established in one 3-week adjunctive trial in adults.

إسرائيل - العبرية - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - asenapine as maleate - טבליות למתן מתחת ללשון - asenapine as maleate 10 mg - asenapine - asenapine - schizophrenia saphris is indicated for the treatment of schizophrenia in adults. the efficacy of saphris was established in two 6-week trials and one maintenance trial in adults bipolar disorder monotherapy: saphris is indicated for the acute treatment of manic or mixed episodes associated with bipolar i disorder. efficacy was established in two 3-week monotherapy trials in adults adjunctive therapy: saphris is indicated as adjunctive therapy with either lithium or valproate for the acute treatment of manic or mixed episodes associated with bipolar i disorder. efficacy was established in one 3-week adjunctive trial in adults.

إسرائيل - العبرية - Ministry of Health

merck sharp & dohme israel ltd - montelukast as sodium 4 mg - granules - montelukast - singulair is indicated in adult and pediatric patients 12 months of age and older for the prophylaxis and chronic treatment of asthma, including prevention of daytime and nighttime symptoms, the treament of aspirin - sensitive asthmatic patients, and the prevention of exercise - induced bronchoconstriction. singulair is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. singulair and inhaled corticosteroids may be used concomitatly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability.

إسرائيل - العبرية - Ministry of Health

merck sharp & dohme israel ltd - montelukast as sodium 4 mg - granules - montelukast - singulair is indicated in adult and pediatric patients 12 months of age and older for the prophylaxis and chronic treatment of asthma, including prevention of daytime and nighttime symptoms, the treament of aspirin - sensitive asthmatic patients, and the prevention of exercise - induced bronchoconstriction. singulair is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. singulair and inhaled corticosteroids may be used concomitatly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability.

إسرائيل - العبرية - Ministry of Health

merck sharp & dohme israel ltd - dorzolamide as hydrochloride 20 mg / 1 ml; timolol as maleate 5 mg / 1 ml - ophthalmic solution - timolol - for the treatment of elevated intraocular pressure (iop) in patients with ocular hypertension, open-angle glaucoma or other secondary open-angle glaucomas when concomitant therapy is appropriate, and in patients who may be sensitive to a preservative, or for whom the use of a preservative-free formulation is otherwise advisable.

إسرائيل - العبرية - Ministry of Health

merck sharp & dohme israel ltd - tafluprost 15 mcg/ml - ophthalmic solution - tafluprost - reduction of elevated intraocular pressure in open angle glaucoma and ocular hypertension.as monotherapy in patients • who would benefit from preservative free eye drops • insufficiently responsive to first line therapy • intolerant or contra-indicated to first line therapyas adjunctive therapy to beta-blockers.

إسرائيل - العبرية - Ministry of Health

merck serono ltd - luteinizing hormone - אבקה להכנת תמיסה לזריקה - luteinizing hormone 75 iu/ml - gonadotropins - luveris in association with a follicle stimulating hormone (fsh) preparation is recommended for the stimulation of follicular development in women with severe lh and fsh deficiency. in clinical trials these patients were defined by an endogenous serum lh level < 1.2 iu/l.

إسرائيل - العبرية - Ministry of Health

merck sharp & dohme israel ltd - protein l1 (type 11) 40 mcg / 0.5 ml; protein l1 (type 16) 40 mcg / 0.5 ml - suspension for injection - gardasil is indicated in females aged 9 through 45 years* for the prevention of cervical, vulvar, vaginal cancer, precancerous or dysplastic lesions, genital warts, and infection caused by human papillomavirus (hpv) types 6, 11, 16, and 18 (which are included in the vaccine). gardasil is indicated in males 9 through 26 years* of age for the prevention of anal cancer, precancerous or dysplastic lesions, external genital lesions and infection caused by hpv types 6, 11, 16, and 18 (which are included in the vaccine). *immunogenicity studies have been conducted to link efficacy in females and males aged 16 to 26 years to the younger populations.

إسرائيل - العبرية - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - rotavirus g1 reassortant; rotavirus g2 reassortant; rotavirus g3 reassortant; rotavirus g4 reassortant; rotavirus p1a[8] reassortant - suspension - rotavirus p1a[8] reassortant 2.3 x10 ^6 iu/dose; rotavirus g2 reassortant 2.8 x10 ^6 iu/dose; rotavirus g4 reassortant 2.0 x10^ 6 iu/dose; rotavirus g3 reassortant 2.2 x10 ^6 iu/dose; rotavirus g1 reassortant 2.2 x10 ^6 iu/dose - rota virus diarrhea vaccines - rotateq is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by the serotypes g1, g2, g3, and g4 when administered as a 3-dose series to infants between the ages of 6 to 32 weeks. the first dose of rorateq should be administered betwen 6 and 12 weeks of age.